InspireMD (NYSE:NSPR) Director Acquires $11,900.00 in Stock

InspireMD, Inc. (NYSE:NSPR) Director Paul Stuka purchased 10,000 shares of the company’s stock in a transaction on Monday, May 11th. The stock was bought at an average price of $1.19 per share, for a total transaction of $11,900.00. Following the completion of the purchase, the director directly owned 632,871 shares of the company’s stock, valued at $753,116.49. The trade was a 1.61% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Paul Stuka also recently made the following trade(s):

• On Friday, May 8th, Paul Stuka acquired 65,626 shares of InspireMD stock. The shares were bought at an average cost of $1.16 per share, for a total transaction of $76,126.16.
• On Thursday, May 7th, Paul Stuka bought 6,378 shares of InspireMD stock. The stock was bought at an average price of $1.15 per share, with a total value of $7,334.70.
• On Wednesday, May 6th, Paul Stuka bought 1,517 shares of InspireMD stock. The stock was bought at an average cost of $1.12 per share, for a total transaction of $1,699.04.

InspireMD Price Performance

Shares of NYSE:NSPR opened at $1.14 on Friday. InspireMD, Inc. has a 12 month low of $1.02 and a 12 month high of $2.93. The firm has a market capitalization of $53.40 million, a P/E ratio of -1.52 and a beta of 0.82. The company’s fifty day moving average price is $1.45 and its 200 day moving average price is $1.71.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of NSPR. Renaissance Technologies LLC acquired a new stake in shares of InspireMD during the first quarter worth about $29,000. Virtu Financial LLC acquired a new position in InspireMD in the 4th quarter valued at about $31,000. XTX Topco Ltd acquired a new position in InspireMD in the 4th quarter valued at about $30,000. Orbimed Advisors LLC raised its stake in InspireMD by 46.9% during the 4th quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock valued at $5,577,000 after acquiring an additional 1,000,000 shares during the last quarter. Finally, Essex Investment Management Co. LLC purchased a new stake in InspireMD during the 4th quarter valued at approximately $203,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Loop Capital set a $5.00 target price on InspireMD in a report on Tuesday, February 24th. Maxim Group started coverage on InspireMD in a research note on Monday, February 2nd. They set a “buy” rating and a $6.00 price target on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 price target (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Finally, Lake Street Capital set a $4.00 price objective on InspireMD in a research note on Monday, May 4th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $4.50.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.